Vantictumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Frizzled receptor |
| Identifiers | |
| CAS Number | 1345009-45-1 |
| ATC code | none |
| Chemical data | |
| Formula | C6322H9722N1674O1988S46 |
| Molecular mass | 142.5 kg/mol |
Vantictumab /vænˈtɪktᵿmæb/ is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by OncoMed Pharmaceuticals Inc.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.(registration required)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with login required references or sources
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies for tumors
